Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Autoinducer-2 (AI-2) quorum sensing pathway is a near-universal bacterial communication system that facilitates both intra- and interspecies signaling by monitoring population density. The pathway is centered around the signaling molecule AI-2, which is synthesized by the LuxS enzyme from S-ribosylhomocysteine as a byproduct of the S-adenosylmethionine (SAM) metabolic cycle (asm.org, nih.gov). Once AI-2 reaches a threshold concentration in the environment, it is recognized by specific receptors such as LuxP in Vibrionaceae or internalized via the LsrABCD transporter and phosphorylated by LsrK in Enterobacteriaceae (nih.gov, wikipedia.org). This signaling cascade regulates critical group behaviors, including the formation of biofilms, the production of virulence factors like toxins and proteases, and the development of antibiotic resistance (frontiersin.org, acs.org). Because the LuxS enzyme is absent in humans and present in over half of all sequenced bacterial species, the AI-2 pathway is a high-priority target for the development of quorum-sensing inhibitors (QSIs) that attenuate pathogenicity without exerting the strong selective pressure of traditional antibiotics (nih.gov, asm.org). Therapeutic strategies currently under investigation include small-molecule inhibitors of LuxS and LsrK, as well as AI-2 analogs that competitively bind to receptors to disrupt bacterial coordination (acs.org, frontiersin.org).
Inhibition of S-ribosylhomocysteine lyase (LuxS) to prevent AI-2 synthesis; inhibition of LsrK kinase to prevent AI-2 phosphorylation; competitive antagonism of AI-2 receptors such as LuxP and LsrB; and interference with the LsrABCD transport system to block signal internalization.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Autoinducer-2 quorum sensing pathway (AI-2 QS).